
PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors
<a href="https://news.google.com/rss/articles/CBMipgJBVV95cUxQMS1nQmFobjBSZndtajJGNXFNbmxJM1BQd0IzeDU5VU94UnA3ZGFtZlc0REt3enZSOWozY0JuWk1lZ19pNHhxaUVOTXpOajVNUWczWTRCdFBkdFBDSWdzbTk1Nm5RTGs2aWo5NW93aFFMVWotdGtXelBDZy1mVzlIQ1hpQ1d1Q0M0OU5Xd05zVHJCUXdmMGNWM1ROQWNSNnB4bDB5TlRtNWZiQlpyX01pZmZaNlFVRXN0aUhMb0tMSkZCUjVOTkF0a0ZsWElLN1lPSkFrTlQ4SnlqTUotazJGNG5pZzEwY3JYODQzT2E0ZW1MbE12SGVjUzJZZjdsVEhFWTlsWjZTUDhwWnFxSGtEWVJRQVFBa3NXWWFVMG9jSmNzeE9tSUE?oc=5" target="_blank">PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>


